Regulus Therapeutics RGLS is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.
Analysts estimate that Regulus Therapeutics will report an earnings per share (EPS) of $-0.07.
Regulus Therapeutics bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Historical Earnings Performance
Last quarter the company missed EPS by $0.02, which was followed by a 3.98% drop in the share price the next day.
Here's a look at Regulus Therapeutics's past performance and the resulting price change:
| Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|
| EPS Estimate | -0.08 | -0.08 | -0.09 | |
| EPS Actual | -0.10 | -0.08 | -0.08 | -0.03 |
| Price Change % | -3.98% | -3.85% | 7.32% | -0.73% |
Stock Performance
Shares of Regulus Therapeutics were trading at $0.2887 as of March 08. Over the last 52-week period, shares are down 82.51%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
To track all upcoming earnings announcements, click here to use Benzinga Earnings Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
